The Marine Pharmacology and Pharmaceuticals Pipeline in 2014

Abstract

In October 2014 there were six FDA‐approved marine‐derived drugs: for cancer, cytarabine (Cytosar‐U®, Depocyt®, FDA‐approved 1969), eribulin mesylate (Halaven®, FDA‐approved 2010), trabectedin (Yondelis®, FDA‐orphan drug approval 2005) being EU‐registered, and brentuximab vedotin (Adcetris®, FDA‐approved 2011); for pain, ziconotide (Prialt®, FDA‐approved 2004); for hypertriglyceridemia omega‐3‐acid ethyl esters (Lovaza®, FDAapproved2004). The clinical marine pharmaceutical pipeline (Mayer et al. TIPS 31:255‐265, 2010) consisted of 10 marine‐derived compounds in clinical development in 2010, including three monoclonal antibodies conjugated to monomethyl auristatin E, a synthetic analog of the marine compound dolastatin, in either Phase I, Phase II or Phase III clinical trials. The current clinical marine pharmaceutical pipeline consists of 9 marine‐derived compounds, and greater than 14 other auristatin‐containing antibody drug conjugates in clinical development. Updated information on the clinical marine pharmaceutical pipeline is available at <a href=“http://marinepharmacology.midwestern.edu/clinPipeline.htm” >http://marinepharmacology.midwestern.edu/clinPipeline.htm</a>. Finally, the global preclinical marine pharmacology pipeline was reviewed in Mayer et al. MARINE DRUGS 11:2510‐2573, 2013). In late 2014, both the marine pharmacology preclinical and clinical pharmaceutical pipelines remained very active. Supported by Midwestern University.